NASDAQ:IMRX

Immuneering Stock Insider Trading

Healthcare > Biotechnology

Buy IMRX

*Your capital is at risk

$4.55

+0.270 (+6.31%)

At Close: Jun 03, 2026

Immuneering Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 5.48M and sold 0 IMRX shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	100.00
● Buy	5.48M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 13, 2026 Buy	Class A Common Stock A-Award	Neufeld Leah R Chief People Officer	Officer	3 628 Value: $15.6K
Feb 03, 2026 Buy	Stock Option A-Award	Bookman Michael Chief Legal Officer, Secretary	Officer	176 000 Value: $864.2K
Feb 03, 2026 Buy	Stock Option A-Award	Brakewood Harold Eugene Chief Business Officer	Officer	140 000 Value: $687.4K
Feb 03, 2026 Buy	Stock Option A-Award	Hall Brett Matthew Chief Scientific Officer	Officer	344 000 Value: $1.69M
Feb 03, 2026 Buy	Stock Option A-Award	Matushansky Igor Chief Medical Officer	Officer	140 000 Value: $687.4K
Feb 03, 2026 Buy	Stock Option A-Award	Morales Mallory SVP Finance, Cao	Officer	140 000 Value: $687.4K
Feb 03, 2026 Buy	Stock Option A-Award	Neufeld Leah R Chief People Officer	Officer	140 000 Value: $687.4K
Feb 03, 2026 Buy	Stock Option A-Award	Zeskind Benjamin J. President And CEO	CEO / President	688 000 Value: $3.38M
Jan 16, 2026 Buy	Class A Common Stock P-Purchase	Brakewood Harold Eugene Chief Business Officer	Officer	5 250 Value: $25.0K
Jan 15, 2026 Buy	Class A Common Stock P-Purchase	Schall Thomas J. Director	Director	21 645 Value: $101.0K
Jan 15, 2026 Buy	Class A Common Stock P-Purchase	Hall Brett Matthew Chief Scientific Officer	Officer	2 298 Value: $10.5K
Jan 13, 2026 Buy	Class A Common Stock P-Purchase	Neufeld Leah R Chief People Officer	Officer	2 626 Value: $10.9K
Jan 12, 2026 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	20 000 Value: $86.9K
Jan 01, 2026 Buy	Stock Option A-Award	Keating Laurie Director	Director	7 888 Value: $51.9K
Jan 01, 2026 Buy	Stock Option A-Award	Feinberg Peter Director	Director	7 888 Value: $51.9K
Oct 03, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	7 500 Value: $50.0K
Oct 03, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	7 500 Value: $50.0K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Morales Mallory Chief Accounting Officer	Officer	300 Value: $2K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Neufeld Leah R Chief People Officer	Officer	800 Value: $5K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Bookman Michael Chief Legal Officer, Secretary	Officer	1 020 Value: $7K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Bookman Michael Chief Legal Officer, Secretary	Officer	1 020 Value: $7K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Neufeld Leah R Chief People Officer	Officer	800 Value: $5K
Oct 01, 2025 Buy	Class A Common Stock P-Purchase	Morales Mallory Chief Accounting Officer	Officer	300 Value: $2K
Sep 30, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	7 500 Value: $52.7K
Sep 30, 2025 Buy	Class A Common Stock P-Purchase	Feinberg Peter Director	Director	7 500 Value: $52.7K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT IMMUNEERING CORPORATION

Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed ...

Read Full Profile Here